Survival of elderly patients with multiple myeloma-Effect of upfront autologous stem cell transplantation
Standard
Survival of elderly patients with multiple myeloma-Effect of upfront autologous stem cell transplantation. / Merz, Maximilian; Jansen, Lina; Castro, Felipe A; Hillengass, Jens; Salwender, Hans; Weisel, Katja; Scheid, Christof; Luttmann, Sabine; Emrich, Katharina; Holleczek, Bernd; Katalinic, Alexander; Nennecke, Alice; Straka, Christian; Langer, Christian; Engelhardt, Monika; Einsele, Hermann; Kröger, Nicolaus; Beelen, Dietrich; Dreger, Peter; Brenner, Hermann; Goldschmidt, Hartmut; GEKID cancer survival working group; German National Registry for Stem Cell Transplants (DRST).
In: EUR J CANCER, Vol. 62, 07.2016, p. 1-8.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Survival of elderly patients with multiple myeloma-Effect of upfront autologous stem cell transplantation
AU - Merz, Maximilian
AU - Jansen, Lina
AU - Castro, Felipe A
AU - Hillengass, Jens
AU - Salwender, Hans
AU - Weisel, Katja
AU - Scheid, Christof
AU - Luttmann, Sabine
AU - Emrich, Katharina
AU - Holleczek, Bernd
AU - Katalinic, Alexander
AU - Nennecke, Alice
AU - Straka, Christian
AU - Langer, Christian
AU - Engelhardt, Monika
AU - Einsele, Hermann
AU - Kröger, Nicolaus
AU - Beelen, Dietrich
AU - Dreger, Peter
AU - Brenner, Hermann
AU - Goldschmidt, Hartmut
AU - GEKID cancer survival working group
AU - German National Registry for Stem Cell Transplants (DRST)
N1 - Copyright © 2016 Elsevier Ltd. All rights reserved.
PY - 2016/7
Y1 - 2016/7
N2 - BACKGROUND: The aim of this study was to determine the value of upfront autologous transplantation (ASCT) in elderly patients (60-79 years) with myeloma.METHODS: We analysed relative survival (RS) of patients diagnosed in 1998-2011 and treated with ASCT within 12 months after diagnosis in Germany (n = 3591; German Registry of Stem Cell Transplantation) and compare RS with survival of myeloma patients diagnosed in the same years in Germany (n = 13,903; population-based German Cancer Registries).RESULTS: Utilisation of ASCT has increased rapidly between 2000-2002 and 2009-2011 (60-64years: 7.0-43.0%; 65-69 years: 6.6-23.7%; 70-79 years: 0.4-4.0%). Comparison of 5-year RS of patients from the general German myeloma population who have survived the first year after diagnosis with 5-year RS of patients treated with ASCT revealed higher survival for transplanted patients among all age groups (60-64: 59.2% versus 66.1%; 65-69: 57.4% versus 61.7%; 70-79: 51.0% versus 56.6%). RS increased strongly between 2003-2005 and 2009-2011 for the general German myeloma population (+8.5%) and for patients treated with ASCT (+11.8%). Differences in RS between these groups increased over time from +1.9% higher age-standardised survival in transplanted patients in 2003-2005 to 5.2% higher survival in 2009-2011.CONCLUSION: We conclude that upfront ASCT might be a major contributor to improved survival for elderly myeloma patients in Germany.
AB - BACKGROUND: The aim of this study was to determine the value of upfront autologous transplantation (ASCT) in elderly patients (60-79 years) with myeloma.METHODS: We analysed relative survival (RS) of patients diagnosed in 1998-2011 and treated with ASCT within 12 months after diagnosis in Germany (n = 3591; German Registry of Stem Cell Transplantation) and compare RS with survival of myeloma patients diagnosed in the same years in Germany (n = 13,903; population-based German Cancer Registries).RESULTS: Utilisation of ASCT has increased rapidly between 2000-2002 and 2009-2011 (60-64years: 7.0-43.0%; 65-69 years: 6.6-23.7%; 70-79 years: 0.4-4.0%). Comparison of 5-year RS of patients from the general German myeloma population who have survived the first year after diagnosis with 5-year RS of patients treated with ASCT revealed higher survival for transplanted patients among all age groups (60-64: 59.2% versus 66.1%; 65-69: 57.4% versus 61.7%; 70-79: 51.0% versus 56.6%). RS increased strongly between 2003-2005 and 2009-2011 for the general German myeloma population (+8.5%) and for patients treated with ASCT (+11.8%). Differences in RS between these groups increased over time from +1.9% higher age-standardised survival in transplanted patients in 2003-2005 to 5.2% higher survival in 2009-2011.CONCLUSION: We conclude that upfront ASCT might be a major contributor to improved survival for elderly myeloma patients in Germany.
KW - Aged
KW - Female
KW - Germany
KW - Humans
KW - Male
KW - Middle Aged
KW - Multiple Myeloma
KW - Retrospective Studies
KW - Stem Cell Transplantation
KW - Survival Analysis
KW - Transplantation, Autologous
KW - Journal Article
U2 - 10.1016/j.ejca.2016.04.004
DO - 10.1016/j.ejca.2016.04.004
M3 - SCORING: Journal article
C2 - 27185572
VL - 62
SP - 1
EP - 8
JO - EUR J CANCER
JF - EUR J CANCER
SN - 0959-8049
ER -